Buzz Stocks: KaloBios Pharmaceuticals Inc, Facebook Inc, and Sunedison Inc

Today's stocks to watch include KaloBios Pharmaceuticals Inc (KBIO), Facebook Inc (FB), and Sunedison Inc (SUNE)

Alex Eppstein

Dec 30, 2015 at 9:27 AM

TERP
D
SUNE
FB
KBIO

Futures are pointed lower this morning, with crude oil in focus ahead of weekly inventory data. Among the equities in focus are drugmaker KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), social network Facebook Inc (NASDAQ:FB), and solar issue Sunedison Inc (NYSE:SUNE).

Just a day after appealing the Nasdaq stock exchange's delisting notice, KBIO filed for Chapter 11 bankruptcy protection. Two weeks ago, the shares settled at $23.59, but haven't traded since -- following the arrest of former CEO Martin Shkreli.

A federal judge has reportedly certified two class action lawsuits against FB, alleging the social network hid growth forecast concerns ahead of its May 2012 initial public offering. As such, the shares are off 0.3% pre-market -- which would be a relatively minor setback, considering the stock has advanced 37.5% year-to-date at $107.26. Nonetheless, option traders have been buying to open bearish bets over bullish at a faster-than-usual rate. Facebook Inc's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.55 ranks in the 88th percentile of its annual range.

SUNE is set to pop 8.2% at the open, following news the company and a group of institutional investors have purchased a 33% stake in a 336 megawatt DC portfolio (subscription required) from Dominion Resources, Inc. (NYSE:D) for $180 million plus a working capital adjustment. Separately, Sunedison Inc announced it will extinguish all of its senior notes due 2020, and will instead offer noteholders its membership equity interest in renewable energy assets under development, as well as class A shares of "yieldco" TerraForm Power Inc (NASDAQ:TERP). On the sentiment front, two-thirds of analysts rate SUNE a "buy" or better -- although the stock was just hit with a price-target cut to $19 from $20 at Cowen and Company. Technically speaking, the shares have done little to warrant optimism, giving up close to three-quarters of their value in 2015, closing Tuesday at $5.02.

Follow @Schaeffers

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earnings guide for Q3 before it's too late!

Special Offers from Schaeffer's Trading Partners